1
                                                                   Exhibit 99(a)

FRIDAY SEPTEMBER 7, 8:16 AM EASTERN TIME

PRESS RELEASE

SOURCE: Neoprobe Corporation

NEOPROBE TO ACQUIRE BLOOD FLOW TECHNOLOGY AND PRODUCTS COMPANY

DUBLIN, Ohio--(BW HealthWire)--Sept. 7, 2001--Neoprobe Corporation (OTCBB:NEOP -
NEWS) today announced that it has entered into a Memorandum of Understanding
(MOU) with Biosonix Ltd. (Biosonix) and its shareholders to acquire all of the
outstanding shares of Biosonix.

Biosonix, located in Hod Hasharon, Israel, has developed a novel
Angle-independent Dual Beam Flow (ADBF) technology that enables surgeons and
other medical personnel to measure in real-time, and in a simple non-invasive
manner, the volume of blood flowing in the vascular circulation as well as a
range of additional hemodynamic parameters. Based on the ADBF core technology
that utilizes digital multi-gated Doppler ultrasound, Biosonix is now in the
process of the commercialization of several blood flow devices to answer the
specific needs of different clinical settings, including the OR (Operating
Room), ICU (Intensive Care Unit), ER (Emergency Room), Neurosurgery and Vascular
Surgery.

"The MOU with Biosonix is consistent with Neoprobe's strategy to expand its
portfolio with products that have near-term commercial potential," said David
Bupp, Neoprobe's president and CEO. "We believe the Biosonix product lines are
very complementary to the core competencies we have developed in medical devices
and represent a substantial business opportunity. In the past several months, we
have announced achievement of a number of milestones regarding activities to
expand our product portfolio, including the commencement of clinical evaluation
of radiopharmaceutical products. The acquisition of Biosonix will allow the
expansion of our product portfolio with a combination of capital equipment and
disposable elements."

The Biosonix Blood Flow Product Series provides innovative solutions to the
accurate quantitative real-time measurements of blood flow and hemodynamic
assessment. The ADBF technology is presently incorporated into three different
products under development: FlowGuard(TM) is designed for a complete
non-invasive vascular diagnosis, primarily in the neurosurgical and vascular
surgery settings. InFlow(TM), an intraoperative system, is designed to replace
qualitative finger palpation or other aggressive technologies with a simple and
immediate quantitative measurement of blood flow. InFlow is intended to be used
by cardiac surgeons to assess blood flow in bypass grafts, native vessels and
the aorta for immediate cardiac output evaluation, as well as for a range of
other applications in vascular surgery, organ transplantation, etc. BioFlow(TM)
is a cardiac function monitor, utilizing a transesophageal approach to measure
blood flow in the descending aorta for continuous assessment of cardiac function
and cardiac output. BioFlow is designed for use with critical care patients in
the ICU, ER and OR environments. It is expected that the first commercial launch
of the Biosonix products will occur next year. Biosonix has estimated the market
potential of its products to be in


   2

excess of $1.5 billion.

Neoprobe will issue a total of approximately 11.8 million of its common shares
to acquire all of the shares of Biosonix. The acquisition of Biosonix is subject
to the completion of due diligence activities by Neoprobe, government consents
regarding the completion of definitive agreements between the parties, and the
satisfaction of other conditions. Neoprobe hopes to complete the transaction by
December 31, 2001.

Statements in this news release which relate to other than strictly historical
facts, such as statements about the Company's plans and strategies, expectations
for future financial performance, new and existing products and technologies,
and markets for the Company's products, are forward-looking statements. The
words "believe," "expect," "anticipate," "estimate," "project," and similar
expressions identify forward-looking statements that speak only as of the date
hereof. Investors are cautioned that such statements involve risks and
uncertainties that could cause actual results to differ materially from
historical or anticipated results due to many factors including, but not limited
to, the Company's limited revenues, accumulated deficit, future capital needs,
uncertainty of capital funding, dependence on limited product line and exclusive
distributor, uncertainty of market acceptance, competition, limited marketing
and manufacturing experience, and other risks detailed in the Company's most
recent Annual Report on Form 10-KSB and other Securities and Exchange Commission
filings. The Company undertakes no obligation to publicly update or revise any
forward-looking statements.

Contact:
     Neoprobe Corporation
     David C. Bupp or Brent L. Larson, 614/793-7500
     info@neoprobe.com
     www.neoprobe.com